Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pazopanib dose hunt in frail seniors halted early

NCT ID NCT01642017

Terminated Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated early, so the full planned enrollment of 30 patients was not reached.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pazopanib (a targeted cancer drug taken as a pill)
What this could lead to
If successful, this could help doctors find a safer dose of pazopanib for frail elderly patients with advanced cancer, potentially offering a treatment option where few exist.
What could go wrong
This is a very early, small phase 1 trial that was terminated early, so results are limited. The drug may still cause significant side effects, and it is not a cure—patients take it until the disease gets worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer pancreatic endocrine carcinoma renal cell carcinoma sarcoma thyroid gland carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER (DIFFERENT SOLID TUMOUR TYPES)

Contacts and locations

Locations

  • Centre François BACLESSE

    Caen, 14076, France

  • Centre Léon BERARD

    Lyon, 69008, France

  • Hôpital Saint André

    Bordeaux, 33075, France

  • Institut Claudius REGAUD

    Toulouse, 31052, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.